TRIP4在黑色素瘤进展中的促肿瘤作用及其参与BRAF靶向治疗反应
该研究探索TRIP4在黑色素瘤中的致癌作用,发现TRIP4在黑色素瘤细胞和组织中高表达,敲低后抑制体外和体内黑色素瘤进展。机制上TRIP4通过间接激活NF-κB及与p300协同直接锚定于COX-2和iNOS启动子调控其表达,并影响BRAF突变细胞对BRAF靶向药的敏感性。
要点
- TRIP4在黑色素瘤细胞和组织中高表达,敲低可抑制增殖、迁移、侵袭并诱导凋亡。
- TRIP4通过NF-κB间接及与p300协同直接调控COX-2和iNOS表达。
- TRIP4高表达与COX-2、iNOS表达正相关且预示100例患者预后不良。
核心结论
- TRIP4具有促肿瘤作用,是候选治疗靶点,TRIP4与BRAF双靶向可能成为黑色素瘤有效治疗策略。
研究设计与样本
- 基于小干扰RNA文库筛选识别TRIP4,并在人黑色素瘤细胞和组织及体内外模型中进行功能与机制研究。
- 临床数据来自100例黑色素瘤患者队列,分析TRIP4表达与COX-2、iNOS表达及预后的相关性。
主要发现
- TRIP4在人类黑色素瘤细胞和组织中高表达。
- 敲低TRIP4抑制黑色素瘤细胞增殖、迁移和侵袭,并诱导凋亡。
- TRIP4部分通过间接激活NF-κB信号、部分通过与p300协同直接锚定于COX-2和iNOS启动子来调控其表达。
- TRIP4调控BRAF突变人黑色素瘤细胞和异种移植瘤对抗BRAF靶向药的敏感性。
- TRIP4高表达与COX-2和iNOS表达升高正相关,并预示100例黑色素瘤患者预后不良。
临床怎么用
- TRIP4高表达可提示黑色素瘤患者预后不良,并可能与COX-2、iNOS表达升高相关。
- 对BRAF突变黑色素瘤,TRIP4表达状态可能影响BRAF靶向治疗敏感性,双靶向TRIP4和BRAF是潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TRIP4 was identified as having a proliferation promoting effect in melanoma cells based on small interfering RNA library screening, however, its precise function in melanoma progression is completely unknown. Here, we explored the carcinogenic role of TRIP4 in melanoma. The high expression of TRIP4 was observed in human melanoma cells and tissues. Its knockdown suppressed melanoma progression in vitro and in vivo, including melanoma cell proliferation, migration, and invasion inhibition and apoptosis induction. Further mechanistic analysis showed that TRIP4 promoted melanoma growth through modulation of COX-2 and iNOS expression partially by activating NF-κB signaling indirectly and partially by the direct anchoring of itself at COX-2 and iNOS promoter via synergy with p300. TRIP4 was confirmed to regulate the sensitivity to anti-BRAF targeted agents in BRAF-mutant human melanoma cells and xenografts. In addition, clinical data showed that high expression of TRIP4 was positively correlated with increased expression of COX-2 and iNOS and predicted poor prognosis in a cohort of 100 melanoma patients. Collectively, these results show a pro-tumorigenic role of TRIP4, provide an insight into the mechanism of TRIP4 as a candidate therapeutic target, and suggest the potential of TRIP4 and BRAF dual targeting as an effective therapeutic strategy for melanoma.
引用
- Hao J, Xu H, Luo M, et al. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy. J Invest Dermatol. 2017. PMID: 28899685. doi:10.1016/j.jid.2017.07.850
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。